Erlotinib for advanced hepatocellular carcinoma

From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China

From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China

From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China

From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China